NCT01488318View on ClinicalTrials.gov

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

August 31, 2016

Conditions

Squamous Cell Carcinoma Of The Head And Neck

Interventions

DRUG

Cetuximab

Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1

DRUG

Dasatinib

Dasatinib 150 mg po

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Julie E. Bauman, MD, MPH

OTHER